These are the flags a further investment must answer — each one specific, each one checkable. We place them by severity, where the flag lands (the core product, the financials, or the subscription), and what it costs to confirm. Five are High, landing on the flagship and the valuation; three are Medium, real exposures that shape the risk. Hover the matrix or any card to read the finding, why it changes the decision, and what to verify next.
The High flags cluster on two surfaces. The core product: apomorphine, the headline differentiator, has no FDA-approved ED use and a withdrawn-product safety record; the arousal benefit is cited at a dose Rugiet does not disclose; the "clinically proven, 3x stronger" claim has no head-to-head study and sits in an active FTC/FDA enforcement lane the BlueChew letter already reached. The financials: company-asserted revenue above $100M does not reconcile with a 51–62-person headcount, and a reported $31M private-credit loan we read as ranking ahead of any new equity is the runway tell. The Medium flags — auto-renewal complaints against reopening FTC negative-option rules, and acquisition economics resting on bought traffic against one revenue line — shape the retention and unit-economics read. Every figure Rugiet supplies carries its company-asserted qualifier; the compounded, not-FDA-approved status of the core product is verified. None of these numbers belongs in a model as independent fact until the verify step closes.